Race impacts outcome in stage III/IV squamous cell carcinomas of the head and neck after concurrent chemoradiation therapy

摘要: BACKGROUND: The purpose of this study was to determine the impact race on outcome in patients with stage III/IV squamous cell carcinoma head and neck (SCCHN) who have completed concurrent chemoradiotherapy. METHODS: authors performed a retrospective analysis 202 SCCHN were treated at University Maryland. Patients received daily radiation total dose 70.2 Gray (Gy) (1.8 Gy/day), concurrently weekly carboplatin (area under curve [AUC] ¼ 2) paclitaxel (45 mg/m 2 ) chemotherapy. RESULTS: There 108 Caucasian (CA) 94 African American (AA) patients. median age 56 years, 81% IV. follow-up 33 months. overall survival (OS) disease-free (DFS) months 19 months, respectively. When analyzed by race, DFS versus 12 (P ¼.028). OS 44 24 ¼.071). 3-year for IV AA CA 29% 50% ¼.031). N2 disease 32% 51% ¼.046). oropharyngeal tumors 30% 60% ¼.006). CONCLUSIONS: This documents inferior They had trend toward worse OS. stratified several prognostic variables, mediocre remains. These data suggest that further investigation into genetic characteristics is warranted. Cancer 2009;115:1744–52. V C 2009 Society.